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Abstract The successful development of a therapeutic agent
targeting treatment of dry eye syndrome necessitates the
demonstration of drug efficacy for both sign and symptom
endpoints. As numerous therapeutic strategies incorporate a
secretagogue function into their overall mechanism of action,
the quantitative assessment of tear production serves as a
logical endpoint to anchor “sign” efficacy. Although several
methods including the Schirmer, the phenol red thread and
tear clearance tests exist, their utility in clinical evaluations
of novel therapeutics is unclear. The purpose of this review is
to summarize findings and conclusions describing the
performance of each of these tests so as to gain insight into
which, if any, is most applicable for use in discovering new
dry eye therapeutics.
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Introduction
The successful development of pharmaceutical agents target-
ing the treatment of dry eye syndrome (keratoconjunctivitis
sicca) requires a definitive demonstration that the drug can
induceasignificant improvement inboth asignanda symptom
of the disease. To this end, the reproducible and sensitive
assessment of signs and symptoms of dry eye is central to the
drug development process. Althoughour knowledge of dryeye
has grown immensely over the last two decades [1],“gold
standard” clinical tests to diagnose dry eye syndrome or gauge
therapeutic effectiveness for dry eye do not exist since no
agents have been approved by the FDA to date for the
treatment of both a sign and symptom of the disease.
Common symptoms experienced by the dry eye patient
vary significantly and include foreign body sensation,
discomfort, dryness, stinging and blurred vision. The
diverse array of dry eye symptoms and their impact on
quality of life has prompted the use of numerous patient
questionnaires, such as the ocular surface disease index
(OSDI®) [2], the dry eye questionnaire [3] and the IDEEL
[4], to objectively quantify symptom improvement in
response to a treatment strategy. A functional improvement
in the amelioration of a sign of the disease adds an
additional level of complexity compared to symptom
assessment due to the fact that there is lack of agreement
as to “what sign” is most relevant. Typically, a measure of
tear production or corneal staining represents the endpoint
upon which drug efficacy will be assessed, but the clear
lack of uniform validated methods [1, 5] to assess either of
these endpoints have limited the utility of these endpoints
for assessing therapeutic efficacy.
Attempts to develop a simple, reproducible clinical test
for the measurement of functional tear production that may
include secretion, flow and/or residual volume date back
over 100 years. At the present time, use of tear clearance/
fluorophotometry, Schirmer strips and phenol red threads
are all recognized as applicable methods. However, each of
these techniques appears to have limitations that may
prevent the accurate interpretation of a drug’s clinical
benefit. Here, we will attempt to highlight the strengths
and weaknesses of these tests to gain objective insight into
their utility in a drug development paradigm.
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Clinically, the Schirmer test is most common and Schirmer
scores, representing the length of wetting (in mm) on the
strip, are routinely used as a key diagnostic criteria for dry
eye. The test involves the insertion of a small piece of filter
paper into the lower fornix of the eye. There are two
variations of the Schirmer test: Schirmer I measures total
tear secretion (basal and reflex). Schirmer II is a measure of
reflex secretion only and involves nasal stimulation
following insertion of the strip. A variation of the Schirmer
I that may allow measurement of basal secretion involves
the application of topical anesthetic prior to strip insertion.
Although performing the Schirmer I with anesthetic may
provide a more accurate picture of basal secretion, the
utility and overall effectiveness of anesthetic administration
in conjunction with the Schirmer is controversial.
Numerous investigators have examined the question of
anesthetic use and although it is clear that tear secretion
generally decreases following topical application, there are
many variables associated with this procedure. Two of the
most relevant are the degree of anesthesia achieved and the
efficiency of blotting residual fluid from the cul-de-sac after
instillation. The general consensus in the literature is that
Schirmer I with anesthesia does not measure true basal
secretion [6–7]. Incomplete anesthesia (including sensation
of the lower lid) and psychogenic variables often serve to
maintain a level of reflex tearing after instillation of the
anesthetic [6–9]. Additionally, use of anesthetic has been
implicated in disruption of cell junctions which may
increase surface staining leading to erroneous conclusions
during the evaluation of surface integrity [10]. As corneal
and/or conjunctival staining is routinely performed after the
Schirmer test, the inclusion of anesthetic may inadvertently
result in misclassification of the presence and/or severity of
dry eye.
Whether with or without the use of anesthetic, numerous
review and research papers have documented high variabil-
ity, low reproducibility and poor correlation with other
signs and symptoms of dry eye [11–16]. Although some of
the variability associated with the Schirmer I test may be
minimized in moderate to severe aqueous deficient dry-eyed
individuals [13], poor reproducibility severely limits the
utility of the this test as a means of quantifying efficacy
relating to dry eye therapy. In an attempt to minimize
variability, numerous variations of the Schirmer test (in
addition to anesthetic use), have been proposed including
closing the eyes, using dim light, reducing the test time and
the use of different filter materials. To date, no such alteration
in methodology has resulted in a consistent improvement in
Schirmer reproducibility or diagnostic sensitivity.
Additional limitations associated with the Schirmer test
have been described in the past 20 years [11, 16].
Included in this list is the fact that the testing time
(5 min) is too long [17, 18]; the paper strip may absorb
tears unevenly (depending on tear composition); there is
potential for evaporative loss; the test causes discomfort
and there is no true agreement for lower “cut off” wetting
length limits in non dry-eyed patients or those with dry
eye disease [19].
If we consider all the vagaries discussed above, it should
not be surprising that there remains a lack of consensus as
to what Schirmer score truly is indicative of dry eye
syndrome. Scores collected without anesthesia ranging
from 5 to <10 mm and <8 mm with anesthesia are generally
regarded as abnormal, signifying the presence of dry eye.
Much of the difficulty in defining wetting limits for
diagnostic purposes can be summarized by a statement
paraphrased from Cho [11] “Schirmer values are too variable
such that no definite limit for normal tear production can be
determined.” Despite significant effort, there have been only
a very small number of studies that have found a wetting cut
off point that is correlated with another sign or symptom of
dry eye. Furthermore, the range of values is such that
regardless of a cut off point, false negative and/or positive
identification of dry-eyed subjects is common. Despite the
paucity of reproducible data, the recent DEWS 2007 report
[19] has suggested a reasonable cutoff value of ≤ 5m mi n5
min for a dry eye diagnosis.
Phenol red thread test
The phenol red thread (PRT) test was introduced in 1982
[20] and was developed to overcome many of the
disadvantages of the Schirmer test as described in the
previous section including high variability, poor reproduc-
ibility, and low sensitivity for detecting dry eyes [20]. The
test consists of a cotton thread impregnated with phenol red
which is pH sensitive. When wet with tears, which are
slightly alkaline, the thread turns from yellow to red. The
“red” portion of the thread is analogous to wetting of the
Schirmer strip and the length of red color in mm is recorded.
Standard clinical data suggests that for a 15-s test, wetting
lengths should normally be between 9 and 20 mm. Patients
with dry eyes have wetting values of less than 9 mm.
Methodologically, the PRT test is similar to the Schirmer
test, although there are some potential advantages that
include the fact that there is little to no sensation from the
thread, thus less potential for reflex. Furthermore, the test
time is only 15 s per eye, the eyes remain open and are free
to blink, and no anesthetic is required [16, 20–24].
Despite these potential advantages, the PRT is used
rarely in clinical practice or in clinical development. Two
possible reasons for this are that the threads are difficult to
handle initially due to their light and flexible nature and the
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supply costly and often requiring special ordering.
Although the PRT test is not a standard clinical test, its
potential advantages over the Schirmer I test have generated
interest in assessing its reproducibility and utility. Several
studies have found the PRT test to be more repeatable than
the Schirmer test (with and without anesthestic) as well as
more reliable in diagnosing dry eye [20, 24–25]. Chiang et
al. [25] compared 66 normal eyes and 14 dry eyes (DE)
using both Schirmer I and PRT. In 28 eyes, both tests were
performed on successive days. Comparing normal to dry
eyes, the following data were reported: normal PRT=20.3±
8.7 mm vs DE PRT=8.1±8.0mm (P<0.005); normal
Schirmer=10.0±7.9 mm vs DE Schirmer=14.6±9.8 mm
(P=0.33). Based on these data, the authors concluded that
the likelyhood of a false positive was 3% using PRT and
18% using Schirmer. An estimate of the reproducibility of
the measurements was achieved through comparison of
data collected on two successive days. The Pearson
coefficient was 0.89 for PRT and only 0.39 for Schirmer.
P a t e le ta l .[ 23] concluded that the PRT test could
accurately differentiate aqueous dry eyed subjects from
non dry-eyed subjects, although in his study, the thread was
left in place for 120 s. In this same study, it was concluded
that the PRT test could not differentiate between dry eye
and non-dry eye if both aqueous and lipid deficient dry-
eyed individuals were lumped together.
From a limited number of studies, it generally appears
that the PRT outperforms the Schirmer test in the areas of
reproducibility and reliability. Global data interpretation
however must proceed with caution, as several of the
studies addressing repeatability were performed on non dry-
eyed subjects, thus calling into question the true utility of
the findings with respect to use in a dry-eyed population.
Nichols et al. [13, 26] analysis of reliability and correlation
of clinical measurements of dry eye have found that
positive correlations do exist between (a) Schirmer and
fluorescein staining, (b) PRT and both fluorescein and rose
Bengal staining, and (c) Schirmer and PRT. What is
disturbing, however, is that although these positive corre-
lations were found, only 31% of dry eye patients had
confirmatory tests for dry eye as evidenced by two positive
tests out of the six possible tests performed to diagnose dry
eye. These tests included fluorescein staining, rose Bengal
staining, PRT, Schirmer, tear meniscus height and tear film
break-up time (TBUT). These finding highlight the poor
correlation that exists between all the tests as well as the
difficulty in selecting entry criteria for a therapeutic drug
study in the dry eye patient population. Saleh [15] suggests
that the poor correlation between tests is as a result of the
fact that each test utilizes a different mechanism to assess
the ocular surface. Therefore, due to the multifactorial
nature of dry eye, many mechanisms do not apply to the
individual dry-eye patient. Saleh [15] further demonstrated
that in a cataract population being screened for surgery,
neither Schirmer nor PRT results agreed with symptoms
(28/103 patients were symptomatic of dry eye based on
questionnaire) and that PRT results showed no correlation
with Schirmer results.
In addition to clinical utility, the question that has
surfaced repeatedly is “what does the PRT actually
measure?” It was originally proposed that the PRT test
measured tear volume. Numerous studies now suggest that
the PRT measures a representation of fluid stored in the
lower cul de sac plus a component of tear secretion (basal
and/or low grade reflex) [16, 23–24]. A true measure of
reflex secretion would require an absorption capacity far in
excess of what a PRT is capable of [16]. In addition, in
15 s, only approximately 0.5 μl of tears or 7.5% of the
average normal volume is collected [16], thus raising the
question of how reliable an overall estimate of volume
could be achieved with the PRT test. It has been suggested
that the ability of the PRT to differentiate aqueous dry-eyed
from non-dry-eyed subjects is due to the tests’ ability to
first absorb the tears naturally present in the lacrimal lake
and then continue to measure the replenishment of fluid
into the lake as a result of basal flow and/or mild
stimulation. Subjects with aqueous deficiency cannot
replenish their fluid as quickly, hence less wetting of the
thread occurs [23]. Blades and Patel [24] have argued that
the length of the PRT test be extended past 15 s as they and
others have demonstrated that wetting is not linear and with
the threads they employed, reached equilibrium in 120 s.
Further adding complexity to our understanding of “what is
being measured” is the possibility that the composition of
the tear fluid can influence wetting length. Both lipids and
mucins can influence flow and it has been demonstrated
that in comparison to migration of saline through a thread,
variable tear composition likely increases the variability of
both PRT and Schirmer measurements [24].
Increased test time may positively influence more than
just differential tear composition and reflex tearing. It is
argued that leaving the thread in for a longer time will
increase the accuracy of the test. For example, the
measuring scale for PRT has a resolution of 1 mm, thus if
mean migration in 15 s=9.2 mm, then resolving power=
(100×1/9.2)%=11%. If the test runs for 60 s and mean
wetting is 18 mm, then resolving power reduces to (100×1/
18)%=5.6%, thus increasing the ability to detect change
and/or differences among test subjects. Perhaps finding the
time that provides the optimal balance between sufficient
time for wetting versus minimal irritation (causing reflex
tearing) is key. This may apply to both Schirmer and PRT
tests [18].
Age and ethnic considerations may also be important in
assessing the utility of functional testing for dry eye. Several
j ocul biol dis inform (2008) 1:1–6 3 3studies have demonstrated that PRT wetting values for non-
dry-eyed subjects are influenced by age (PRT reduces as age
increase) and by race [PRT values are lower in American
Caucasians compared to Japanese (living in Japan)] [20, 24].
In summary, although rarely used, the PRT may offer an
advantage over the Schirmer test with respect to increased
measurement reproducibility. To this end, it may provide
both better diagnostic utility as well as serve as a more
meaningful tool for therapeutic drug evaluation. The PRT
test, however, still demonstrates variability and compro-
mised reproducibility due to patient variation in the volume,
depth, and shape of the lacrimal lake, the temperature of the
environment in which the test is performed and the
variation in tear composition among patients. Additionally,
the threads are difficult to handle and insert thus necessi-
tating appropriate training. Further research on timing of
the test and perhaps the use of a closed eye [27] may further
refine reproducibility.
Tear film fluorophotometry/fluorescein clearance
As noted above, neither the Schirmer nor the PRT appear
ideal for the accurate and reproducible quantitation of tear
production. However, alternative, more dynamic methods
have been established utilizing the rate of disappearance of
a tracer as the functional readout. Lacrimal scintigraphy is
one such method, which involves the application of a
radioactive tracer such as technetium 99 (99M Tc) into the
lower marginal tear strip [28, 29]. The distribution of the
tracer is monitored by a gamma counter, and the rate of
change or transit time of the tracer through the system
provides an estimate of tear turnover. Although various
quantitative algorithms have been proposed for this
approach [30], the widespread clinical use of a radioisotope
in humans is both undesirable and impractical. Thus,
methods utilizing fluorescence rather than radioactive decay
were developed to enable assessment of tear turnover.
Following topical ocular application, fluorescein sodium
is thought to be distributed homogenously on the corneal
surface and conjunctival sac after several blinks. Immedi-
ately thereafter, tears containing fluorescein are removed by
flow and are replaced by fresh tears not containing
fluorescein. The measurement of fluorescein disappearance
via fluorophotometry or other fluorescein clearance tests is
used to determine tear turnover which is defined as the
percentage decrease of fluorescein concentration in tears per
unit of time (% minute
-1). Basal tear turnover, defined as the
tear turnover at the lowest level of reflex tear production
possible under physiologic conditions, is then utilized as an
indirect quantitative assessment of tear production.
Numerous methodological variations of fluorescein
clearance have been proposed. Early studies with in vivo
fluorophotometry utilized a modified slit lamp; however,
commercially available instruments (i.e., the Fluorotron
Master) have greatly aided in the standardization of
clearance measurements. Typically, 1 to 5 μl of sodium
fluorescein are applied to the ocular surface and fluores-
cein concentration is measured at various intervals for a
d u r a t i o no f1 5t o3 0m i n[ 30–33]. The change is rate of
decay of fluorescence is calculated for the entire test
duration. Typically, a biphasic decay is observed, with the
first 5 min representing initial reflex tearing after which
(5 min outward), basal conditions of secretion are
represented [34]. It is this second phase of the curve that
is used to extrapolate basal tear turnover. Tear turnover
data can then be transformed to flow and/or volume
estimates [30].
As alternative approaches to fluorophotometry, two
indirect or ex vivo measures have been proposed. The first,
introduced by Xu and Tsubota [35], is a modification of the
Schirmer test with anesthesia. Five minutes after co-
application of fluoroescein and anesthetic, Schirmer strips
are inserted. The length of wetting is recorded after 5 min
and the intensity of strip staining is compared to a standard
color plate. Although clinically practical, this approach has
been criticized for being semi-quantitative at best. Thus, as
a potential improvement, Afonso et al. [7] described a
method where following instillation of fluorescein, tears
were collected with a porous polyester rod. Dye is eluted
from the rod then quantified in a fluorescence multiplate
reader.
Data reported in the literature using each of these
techniques suggest that measurement of tear clearance
provides a more reliable and objective endpoint for the
diagnosis of dry eye compared to Schirmer or PRT [30–39].
However, numerous limitations remain. Tear film fluoro-
photometry remains predominantly a research tool due to
the cost of the instrumentation required to perform such
studies. In addition, precision and accuracy are still subject
to error from several sources. First, any disturbance of the
corneal surface, such as occurs in dry eye, may alter the
corneal uptake of fluorescein from the tear film. This can
result in a change to the monoexponential decay rate of
fluorescein used in the calculation of tear production [30, 38].
Therefore, in clinical studies used to asses the efficacy of
drugs to treat dry eye, an improvement of the ocular surface
may in and of itself change the measured rate of tear
clearance which could be falsely attributed to the effect of
the test drug. Additional sources of error in tear film
fluorophotometry may arise from reflex lacrimation, changes
in tear film thickness, and corneal autofluorescence.
With respect to the alternative measures of tear clearance,
reflex tearing following Schirmer insertion and/or tear
collection pose a significant variable. Additionally, expensive
instrumentation is required for quantitation of fluorescein
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dyed Schirmer strips is complicated by the fact that
fluorescein intensity will be affected by the length of strip
wetting [39]. Applicable to all tear clearance methods are
anatomical influences (lid laxity, blink abnormalities, func-
tional tear outflow obstruction) and optimal timing and dye
volume variables. The last point to address is the fact that
tear turnover measured by any of these tests is not a direct or
independent measure of tear production [7, 30]. As described
by Afonso et al. [7], delayed tear clearance occurs in both
aqueous tear deficient dry eye as well as “Schirmer normal”
subjects. This group and others have suggested that tear
clearance values may correlate well with ocular irritation
symptoms and/or inflammation of the ocular surface [7, 32],
but whether or not true measures of production or volume
can be made remains to be tested.
Conclusion
As evidenced by the DEWS 2007 [1] report, considerable
progress has been made in our understanding of the
epidemiology, pathophysiology, and diagnosis of dry eye.
Clinically, it appears clear that no single test is capable of
repeatedly differentiating dry-eyed from non-dry-eyed
individuals. In this review, we have highlighted the fact
that although tests such as the Schirmer, PRT, and
fluorophotometry may all be employed to assess clinical
endpoints, numerous variables associated with each may
contribute to poor test reproducibility and poor correlation
to the clinical improvement that accompanies the use of a
therapeutic agent. Fluorophotometry offers the greatest
potential for providing an accurate assessment of tear
production. Although unconventional, the PRT appears to
offer the next best accuracy and reproducibility followed by
the Schirmer test. It is particularly disconcerting that of all
these tests, few if any correlate with each other to a
significant degree. From the perspective of therapeutic
development, these diagnostic shortcomings translate into a
significant obstacle as evidenced by the fact that regulatory
agency approval of a therapeutic agent that improves both a
sign and symptom endpoint has been elusive. Due to the
limitations of obtaining and measuring select endpoints to
assess tear function regardless of the test used, it is
reasonable to ask if the main reason we do not yet have
an approved drug to treat dry eye syndrome is because a
given drug simply lacks clinical robustness, or rather,
because there are significant quantitative limitations in the
methods currently used to demonstrate the clinical robust-
ness of a particular drug? Of concern is that regardless of
the tear function test used, it appears that none of these tests
may ultimately possess the reproducibility, sensitivity, and/
or robustness to serve as a reliable and reproducible
quantitative assessment of tear volume. Continued efforts
in method development will surely be required in order to
validate and characterize tear function endpoints used in
clinical trials to support the approval of a drug for dry eye
therapy.
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